DE69941719D1 - Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden - Google Patents

Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden

Info

Publication number
DE69941719D1
DE69941719D1 DE69941719T DE69941719T DE69941719D1 DE 69941719 D1 DE69941719 D1 DE 69941719D1 DE 69941719 T DE69941719 T DE 69941719T DE 69941719 T DE69941719 T DE 69941719T DE 69941719 D1 DE69941719 D1 DE 69941719D1
Authority
DE
Germany
Prior art keywords
present
mage
ctl clones
isolated
ctl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941719T
Other languages
English (en)
Inventor
Pascal Chaux
Rosalie Luiten
Nathalie Demotte
Marie-Therese Duffour
Christophe Lurquin
Catia Traversari
Vincent Stroobant
Guy R Cornelis
Thierry Boon-Falleur
Der Bruggen Pierre Van
Erwin Schultz
Guy Warnier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Priority claimed from PCT/IB1999/001664 external-priority patent/WO2000020445A2/en
Application granted granted Critical
Publication of DE69941719D1 publication Critical patent/DE69941719D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69941719T 1998-10-02 1999-09-15 Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden Expired - Lifetime DE69941719D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/165,863 US6407063B1 (en) 1998-10-02 1998-10-02 Tumor antigens and CTL clones isolated by a novel procedure
US09/289,350 US6531451B1 (en) 1998-10-02 1999-04-09 Tumor antigens and CTL clones isolated by a novel procedure
PCT/IB1999/001664 WO2000020445A2 (en) 1998-10-02 1999-09-15 Tumor antigens and ctl clones isolated by a novel procedure

Publications (1)

Publication Number Publication Date
DE69941719D1 true DE69941719D1 (de) 2010-01-07

Family

ID=22600796

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941719T Expired - Lifetime DE69941719D1 (de) 1998-10-02 1999-09-15 Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden

Country Status (4)

Country Link
US (2) US6407063B1 (de)
JP (1) JP4722289B2 (de)
AT (1) ATE449787T1 (de)
DE (1) DE69941719D1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69533295T3 (de) * 1994-02-16 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, The Department Of Health And Human Services Melanoma-assoziierte Antigene, Epitope davon und Impstoffe gegen Melanoma
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US5965381A (en) * 1998-03-06 1999-10-12 Ludwig Institute For Cancer Research Delivery of proteins into eukaryotic cells with recombinant yersinia
AU1013701A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
AU5810201A (en) * 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
US7786278B2 (en) * 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
JP4668919B2 (ja) * 2003-10-08 2011-04-13 サノフィ パストゥール インコーポレイテッド 修飾ｃｅａ／ｂ７ベクター
EP1697399B1 (de) 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitop humaner zytotoxischer t-lymphozyten und dessen agonistenepitop aus der nichtvariablen zahl der tandem-wiederholungssequenz von muc-1
JP2008505106A (ja) * 2004-07-01 2008-02-21 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア ハイスループットプロテオミクス
CN101041816B (zh) * 2006-12-01 2010-08-25 扬州大学 人工抗原递呈细胞及其制备方法
US8313894B2 (en) 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
JP7204484B2 (ja) * 2016-04-08 2023-01-16 アダプティミューン・リミテッド Ｔ細胞受容体
JP2020514378A (ja) 2017-03-20 2020-05-21 ジェノセア バイオサイエンシーズ， インコーポレイテッド 処置方法
EP3806888B1 (de) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
CN114174327A (zh) 2019-03-08 2022-03-11 黑曜石疗法公司 用于可调整调控的cd40l组合物和方法
KR20210149251A (ko) 2019-03-08 2021-12-08 옵시디안 테라퓨틱스, 인크. 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
BR112021025022A2 (pt) 2019-06-12 2022-02-22 Obsidian Therapeutics Inc Composições de ca2 e métodos para regulação ajustáveis
US20220267398A1 (en) 2019-06-12 2022-08-25 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021040736A1 (en) 2019-08-30 2021-03-04 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
CN115210250A (zh) 2020-01-08 2022-10-18 黑曜石疗法公司 用于可调节性调控转录的组合物和方法
CN111534546A (zh) * 2020-05-09 2020-08-14 赛诺（深圳）生物医药研究有限公司 一种具有多等位基因p53编码序列的重组腺病毒的制备方法
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
US5558995A (en) 1993-01-22 1996-09-24 Ludwig Institute For Cancer Research Peptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereof
US6328971B1 (en) 1993-01-22 2001-12-11 Ludwig Institute For Cancer Research MAGE-1 derived nona peptides, and compositions thereof
AU702517B2 (en) * 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
WO1997026328A1 (en) * 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US6265215B1 (en) 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
JP2002507397A (ja) * 1998-03-13 2002-03-12 エピミューン，インコーポレイティド Ｈｌａ結合ペプチド及びその使用

Also Published As

Publication number Publication date
US6531451B1 (en) 2003-03-11
US6407063B1 (en) 2002-06-18
ATE449787T1 (de) 2009-12-15
JP2003518911A (ja) 2003-06-17
JP4722289B2 (ja) 2011-07-13

Similar Documents

Publication Publication Date Title
DE69941719D1 (de) Tumorantigene und ctl-klone, die durch ein neues verfahren isoliert wurden
WO2000020445A3 (en) Tumor antigens and ctl clones isolated by a novel procedure
von Boehmer The selection of the α, β heterodimeric T-cell receptor for antigen
US10968430B2 (en) Use of specific regulatory T-cells to induce immune tolerance
Bozzacco et al. Mass spectrometry analysis and quantitation of peptides presented on the MHC II molecules of mouse spleen dendritic cells
Kimura et al. cell surface glycoproteins of murine cytotoxic T lymphocytes. I. T 145, a new cell surface glycoprotein selectively expressed on Ly 1-2 (+) cytotoxic T lymphocytes
Tonegawa The molecules of the immune system
de Koster et al. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP.
Anderson et al. Fibroblast dependency during early thymocyte development maps to the CD25+ CD44+ stage and involves interactions with fibroblast matrix molecules
DK0512112T3 (da) Anti-CD4-antistoffer, som blokerer HIV-inducerede syncytier
ES2531142T3 (es) Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden
PT994903E (pt) Metodos e composicoes para glicoproteinas galactosiladas
AR018064A1 (es) Proteina de fusion que consiste en un antigeno asociado a tumores derivado de la familia mage, secuencia de acido nucleico que la codifica, vector que lo comprende, celula huesped que no puede generar un individuo completo transformada con dicho acido nucleico, vacuna que contiene dicha proteina, su
Kohler et al. Cross‐reactive trinitrophenylated peptides as antigens for class II major histocompatibility complex‐restricted T cells and inducers of contact sensitivity in mice. Limited T cell receptor repertoire
NO963918D0 (no) Isolerte peptider avledet fra tumor-rejeksonsforlöperen MAGE-2, samt anvendelse derav
BR9809656A (pt) Composição imunopotencializante
CN112639136A (zh) 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法
Golstein et al. Mouse T cell-mediated cytolysis specifically triggered by cytophilic xenogeneic serum determinants: A caveat for the interpretation of experiments done under “syngeneic” conditions
Bergman et al. Characterization of H+, K+‐ATPase T cell epitopes in human autoimmune gastritis
WAKSMAN Overview: Biology of the lymphokines
TW200611706A (en) Cytotoxic t lymphocyte
Guimezanes et al. A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product
RU2005106841A (ru) Эпитопы т-клеток в эритропоэтине
DE69833455D1 (de) Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs)
MX2022003432A (es) Metodos y composiciones que comprenden un anticuerpo monoclonal antictla4 con proteinas de celulas hospederas reducidas y estabilidad del polisorbato-80 aumentada.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition